Wainberg Weighs In on Advances in HER2+ GI Cancers

Season 5 Episode 23  ·  Jul 12, 2021, 07:57 PM

Headliner
Share
Subscribe

In our exclusive interview, Wainberg discussed factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more!

Share
Subscribe
Next
Mayer on the Optimization of SERDs in ER+ Breast Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air